Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against Pseudomonas aeruginosa in a mouse lung infection model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 3, 2017, Pages

  Lin, Yu Wei ^a   Zhou, Qi Tony ^b   Cheah, Soon Ee ^c   Zhao, Jinxin ^c   Chen, Ke ^c   Wang, Jiping ^c   Chan, Hak Kim ^a   Li, Jian ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PURDUE UNIVERSITY   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Colistin; Intratracheal administration; Mouse lung infection model; Multidrugresistant bacteria; Pharmacodynamics; Pharmacokinetics; Pseudomonas aeruginosa; Respiratory tract infection

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; EPITHELIAL LINING FLUID; FEMALE; LUNG EPITHELIUM; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNBOUND FRACTION; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; BODY MASS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; ENDOTRACHEAL INTUBATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA; STATISTICAL MODEL;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; BRONCHOALVEOLAR LAVAGE FLUID; COLISTIN; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; INTUBATION, INTRATRACHEAL; LUNG; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA;

EID: 85014191146     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02025-16     Document Type: Article

References (44)

1. Geller DE. 2009. Aerosol antibiotics in cystic fibrosis. Respir Care 54: 658-670. https://doi.org/10.4187/aarc0537.
2. Mohamed AF, Cars O, Friberg LE. 2014. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. J Antimicrob Chemother 69:1350-1361. https://doi.org/10.1093/jac/dkt520.
3. Agrafiotis M, Siempos I, Ntaidou T, Falagas M. 2011. Attributable mortality of ventilator-associated pneumonia: a meta-analysis. Int J Tuberc Lung Dis 15:1154-1163. https://doi.org/10.5588/ijtld.10.0498.
4. Cheah S-E, Wang J, Turnidge JD, Li J, Nation RL. 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother 70:3291-3297.
5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601. https://doi.org/10.1016/S1473-3099(06)70580-1.
6. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier J-C, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob Agents Chemother 54:3702-3707. https://doi.org/10.1128/AAC.00411-10.
7. Yapa SW, Li J, Porter CJ, Nation RL, Patel K, McIntosh MP. 2013. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob Agents Chemother 57:5087-5095. https://doi.org/10.1128/AAC.01127-13.
8. Gontijo AVL, Grégoire N, Lamarche I, Gobin P, Couet W, Marchand S. 2014. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin. Antimicrob Agents Chemother 58:3950-3956. https://doi.org/10.1128/AAC.02819-14.
9. Yapa SW, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ. 2014. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58:2570-2579. https://doi.org/10.1128/AAC.01705-13.
10. Hansen C, Pressler T, Høiby N. 2008. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 7:523-530. https://doi.org/10.1016/j.jcf.2008.06.009.
11. Döring G, Conway S, Heijerman H, Hodson M, Høiby N, Smyth A, Touw D, Committee C. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16:749-767. https://doi.org/10.1034/j.1399-3003.2000.16d30.x.
12. Nakwan N, Lertpichaluk P, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. 2015. Pulmonary and systemic pharmacokinetics of colistin following a single dose of nebulized colistimethate in mechanically ventilated neonates. Pediatr Infect Dis J 34:961-963. https://doi.org/10.1097/INF.0000000000000775.
13. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F, Becquemin M-H, Le Naour G, Marquette C-H. 2010. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 36:1147-1155. https://doi.org/10.1007/s00134-010-1879-4.
14. Chiang S-R, Chuang Y-C, Tang H-J, Chen C-C, Chen C-H, Lee N-Y, Chou C-H, Ko W-C. 2009. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med 37:2590-2595. https://doi.org/10.1097/CCM.0b013e3181a0f8e1.
15. Velkov T, Rahim NA, Zhou QT, Chan H-K, Li J. 2015. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv Drug Deliv Rev 85:65-82. https://doi.org/10.1016/j.addr.2014.11.004.
16. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. https://doi.org/10.1086/595011.
17. Rennard S, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin P, Crystal R. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60:532-538.
18. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Frame-work for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:225-234.
19. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48:1724-1728. https://doi.org/10.1086/599225.
20. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19:831-838. https://doi.org/10.1093/jac/19.6.831.
21. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958. https://doi.org/10.1128/AAC.00035-06.
22. Yapa SW. 2013. Ph.D. thesis. Monash University, Melbourne, Victoria, Australia.
23. Bosquillon C. 2010. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci 99:2240-2255. https://doi.org/10.1002/jps.21995.
24. Lu X, Chan T, Xu C, Zhu L, Zhou QT, Roberts KD, Chan H-K, Li J, Zhou F. 2016. Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins. J Antimicrob Chemother 71:403-412. https://doi.org/10.1093/jac/dkv340.
25. Lu H, Klaassen C. 2006. Tissue distribution and thyroid hormone regulation of Pept1 and Pept2 mRNA in rodents. Peptides 27:850-857. https://doi.org/10.1016/j.peptides.2005.08.012.
26. Jin L, Li J, Nation RL, Nicolazzo JA. 2011. Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. Antimicrob Agents Chemother 55:502-507. https://doi.org/10.1128/AAC.01273-10.
27. Boisson M, Jacobs M, Grégoire N, Gobin P, Marchand S, Couet W, Mimoz O. 2014. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 58:7331-7339. https://doi.org/10.1128/AAC.03510-14.
28. Kiem S, Schentag JJ. 2008. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 52:24-36. https://doi.org/10.1128/AAC.00133-06.
29. Schwameis R, Erdogan-Yildirim Z, Manafi M, Zeitlinger M, Strommer S, Sauermann R. 2013. Effect of pulmonary surfactant on antimicrobial activity in vitro. Antimicrob Agents Chemother 57:5151-5154. https://doi.org/10.1128/AAC.00778-13.
30. Huang JX, Blaskovich MA, Pelingon R, Ramu S, Kavanagh A, Elliott AG, Butler MS, Montgomery AB, Cooper MA. 2015. Mucin binding reduces colistin antimicrobial activity. Antimicrob Agents Chemother 59: 5925-5931. https://doi.org/10.1128/AAC.00808-15.
31. Kunin CM, Bugg A. 1971. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J Infect Dis 124:394-400. https://doi.org/10.1093/infdis/124.4.394.
32. Bysani GK, Stokes DC, Fishman M, Shenep JL, Hildner WK, Rufus K, Bradham N, Costlow ME. 1990. Binding of polymyxin B to rat alveolar macrophages. J Infect Dis 162:939-943. https://doi.org/10.1093/infdis/162.4.939.
33. Brody JS, Vaccaro CA, Hill NS, Rounds S. 1984. Binding of charged ferritin to alveolar wall components and charge selectivity of macromolecular transport in permeability pulmonary edema in rats. Circ Res 55:155-167. https://doi.org/10.1161/01.RES.55.2.155.
34. Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette C-H, Rouby J-J. 2002. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 166:1375-1381. https://doi.org/10.1164/rccm.200204-363OC.
35. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. 2004. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 3:23-28. https://doi.org/10.1016/j.jcf.2003.12.005.
36. Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, Tanabe Y, Gejyo F, Yamaguchi K. 2009. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63:534-542. https://doi.org/10.1093/jac/dkn530.
37. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2010. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 54: 1117-1124. https://doi.org/10.1128/AAC.01114-09.
38. Dudhani RV, Turnidge JD, Nation RL, Li J. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65:1984-1990. https://doi.org/10.1093/jac/dkq226.
39. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd information supplement M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
40. Hengzhuang W, Wu H, Ciofu O, Song Z, Høiby N. 2012. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agents Chemother 56:2683-2690. https://doi.org/10.1128/AAC.06486-11.
41. Bivas-Benita M, Zwier R, Junginger HE, Borchard G. 2005. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 61:214-218. https://doi.org/10.1016/j.ejpb.2005.04.009.
42. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46:3304-3307. https://doi.org/10.1128/AAC.46.10.3304-3307.2002.
43. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761:167-175. https://doi.org/10.1016/S0378-4347(01)00326-7.
44. Roberts KD, Azad MA, Wang J, Horne AS, Thompson PE, Nation RL, Velkov T, Li J. 2015. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant gram-negative bacteria. ACS Infect Dis 1:568-575. https://doi.org/10.1021/acsinfecdis.5b00085.